Ian A. Prior

RAS inhibition limits oncogenic signaling and tumorigenesis in neuroblastoma regardless of RAS mutational status

Abstract Neuroblastoma (NBL) is a rare and aggressive pediatric malignancy with a 5-year survival rate of 40–50% for patients diagnosed with high-risk disease. NBLs arise in the sympathetic nervous system and causes 11% of all pediatric cancer deaths. MYCN amplification or overex...